These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 1428725)
61. Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. Nichols CR; Loehrer PJ; Greist A; Kubilis PS; Hoffman R Med Pediatr Oncol; 1988; 16(1):12-6. PubMed ID: 3340061 [TBL] [Abstract][Full Text] [Related]
62. Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer. Hsieh RK; Chang AY; Boros L; Asbury R Am J Clin Oncol; 1994 Dec; 17(6):509-13. PubMed ID: 7977171 [TBL] [Abstract][Full Text] [Related]
64. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer. Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076 [TBL] [Abstract][Full Text] [Related]
65. Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer. Araujo CE; Cervellino JC; Pirisi C; Pannunzio O; Callegari J J Surg Oncol; 1991 Mar; 46(3):198-202. PubMed ID: 1901372 [TBL] [Abstract][Full Text] [Related]
66. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741 [TBL] [Abstract][Full Text] [Related]
67. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Coleman M; Leonard J; Shuster MW; Kaufman TP Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401 [TBL] [Abstract][Full Text] [Related]
68. Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy. Scheulen ME; Bremer K; Niederle N; Seeber S Cancer Treat Rev; 1983 Sep; 10 Suppl A():137-43. PubMed ID: 6627240 [TBL] [Abstract][Full Text] [Related]
69. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. Bokemeyer C; Schmoll HJ; Ludwig E; Harstrick A; Dunn T; Casper J Br J Cancer; 1994 May; 69(5):863-7. PubMed ID: 8180015 [TBL] [Abstract][Full Text] [Related]
70. Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Cervellino JC; Araujo CE; Sánchez O; Miles H; Nishihama A Acta Oncol; 1995; 34(2):257-9. PubMed ID: 7718266 [TBL] [Abstract][Full Text] [Related]
71. Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study. Tigaud JD; Demolombe S; Bastion Y; Bryon PA; Coiffier B Hematol Oncol; 1991; 9(4-5):225-33. PubMed ID: 1743625 [TBL] [Abstract][Full Text] [Related]
72. Dosing and side-effects of ifosfamide plus mesna. Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007 [TBL] [Abstract][Full Text] [Related]
73. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer. Thongprasert S J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902 [TBL] [Abstract][Full Text] [Related]
74. [Salvage chemotherapy of non-seminomatous germ cell tumors. Phase II trial of a combination of etoposide, ifosfamide and high-dose cisplatin]. Ribrag V; Droz JP; Bouleuc C; Theodore C; Ghosn M; Pico JL; Azab M; Ostronoff M; Hayat M Presse Med; 1990 Jul 7-14; 19(27):1263-6. PubMed ID: 2143824 [TBL] [Abstract][Full Text] [Related]
76. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710 [TBL] [Abstract][Full Text] [Related]
77. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer. Araujo CE; Tessler J Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369 [TBL] [Abstract][Full Text] [Related]
78. Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer. Chen YM; Wu MF; Perng RP; Chou CM; Yang KY; Lin WC; Tsai CM; Liu JM; Whang-Peng J Jpn J Clin Oncol; 1997 Apr; 27(2):76-9. PubMed ID: 9152794 [TBL] [Abstract][Full Text] [Related]
79. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer. Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386 [TBL] [Abstract][Full Text] [Related]
80. VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer. Evans WK; Stewart DJ; Shepherd FA; Logan D; Goss G; Maroun JA; Wierzbicki R; Warner E; Latreille J; Dahrouge S Eur J Cancer; 1994; 30A(3):299-303. PubMed ID: 8204348 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]